 |
 |
Jorge Romero reported a warning: "Patients receiving [Mirapex] have reported falling asleep ... " A more extensive text can be found in (1) a letter from the manufacturer to prescribers, and (2) in a revision of the FDA safety information. Those two documents [and many others] pop up if you go to http://www.fda.gov/search.html and search on Mirapex. [Many thanks to Murray Charters for pointing us to the FDA.] The FDA document contains the following: "some [patients] perceived that they had no warning signs such as excessive drowsiness, and believed that they were alert immediately prior to the event". -- So it would seem that Bob Armentrout's ability to detect an oncoming sleep-attack is not universal. The FDA document also contains the following: "In a fixed-dose study in early Parkinson's disease, occurrence of the following events increased in frequency as the dose increased over the range from 1.5 mg/day to 6 mg/day: postural hypotension, nausea, constipation, somnolence, and amnesia. The frequency of these events was generally 2-fold greater than placebo for pramipexole doses greater than 3 mg/day. The incidence of somnolence with pramipexole at a dose of 1.5 mg/day was comparable to that reported for placebo. ... ". -- So it would seem that Mirapex at up to 1.5 mg/day _may_ be 'safe' as far as sleep-attacks are concerned. Given our North-American dependence on cars, where most of us almost _cannot function_ without driving, I wonder whether someone is working on a 'no-doz' form of pramipexole or ropinirole. Ben Winter 66/66/64 Victoria BC Canada